Histogen (Histogen) Total Liabilities : $1.41 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen Total Liabilities?

Histogen's Total Liabilities for the quarter that ended in Sep. 2023 was $1.41 Mil.

Histogen's quarterly Total Liabilities declined from Mar. 2023 ($5.73 Mil) to Jun. 2023 ($5.28 Mil) and declined from Jun. 2023 ($5.28 Mil) to Sep. 2023 ($1.41 Mil).

Histogen's annual Total Liabilities declined from Dec. 2020 ($8.10 Mil) to Dec. 2021 ($7.06 Mil) and declined from Dec. 2021 ($7.06 Mil) to Dec. 2022 ($5.70 Mil).

Histogen Total Liabilities Historical Data

The historical data trend for Histogen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Total Liabilities Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Total Liabilities

40.91

8.10

7.06

5.70

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial													5.93	5.70	5.73	5.28	1.41

Histogen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Histogen's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.234	+	(4.384	+	-2.6367796834847E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.079	+	0)
	=	5.70

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	19.073	-	13.376
	=	5.70

Histogen's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.348	+	(0	+	-5.5511151231258E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.065	+	0)
	=	1.41

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	5.817	-	4.404
	=	1.41

Histogen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Histogen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (Histogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Executives

Joyce Reyes	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann	director	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson	officer: See Remarks	9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson	director, 10 percent owner	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton	officer: See Remarks	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang	director	12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich	officer: See Remarks	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall	officer: EVP, COO & CFO	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127